In this article, we are going to delve into Radequinil, a topic that has aroused great interest in today's society. Radequinil is a concept that has gained relevance in various fields, from science to popular culture, and its influence has spread significantly in recent times. Along these lines, we will explore the different facets and dimensions of Radequinil, analyzing its impact on everyday life, its relevance in the academic field, as well as its presence in technology and entertainment. Through a multidisciplinary approach, we aim to shed light on Radequinil and offer a comprehensive view of this phenomenon that has captured the attention of numerous individuals and groups in contemporary society.
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H14N4O3 |
Molar mass | 334.335 g·mol−1 |
3D model (JSmol) | |
| |
|
Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor.[1] It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.[1][2]